IMARC Group, a leading market research company, has recently releases report titled “Macular Degeneration Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The global macular degeneration treatment market size reached US$ 8.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 12.9 Billion by 2028, exhibiting a growth rate (CAGR) of 6.2% during 2023-2028.

Industry Overview of Macular Degeneration Treatment

Macular degeneration treatment refers to medical interventions and therapies that focus on managing and mitigating the effects of macular degeneration, which is a progressive eye condition. It comprises a range of strategies, such as medication, surgical procedures, and lifestyle modifications, to improve visual function in individuals afflicted by this condition. It can be treated through anti-angiogenic drugs that prevent blockages and leakages in the blood vessels.   

Request Sample Copy of This Report: https://www.imarcgroup.com/macular-degeneration-treatment-market/requestsample

What are the growth prospects and trends in the macular degeneration treatment industry?

At present, the rising awareness about the importance of early disease detection among individuals, along with the improved diagnostic methods that enhance treatment effectiveness, represents one of the major factors strengthening the growth of the market.

Besides this, the increasing preference for gene therapy and regenerative medicine that offer promising prospects for innovative macular degeneration is contributing to the growth of the market. Moreover, the rising popularity of personalized medicine to improve patient outcomes due to the increasing focus on patient-centric approaches in healthcare facilities worldwide is bolstering the growth of the market.

Apart from this, the growing demand for effective treatments and therapies due to the rising incidences of macular degeneration among individuals across the globe is positively influencing the market. In line with this, the increasing number of insurance coverage policies for eye care and treatments to reduce financial barriers for patients is supporting the growth of the market. 

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Type:

  • Dry Age-related Macular Degeneration
  • Wet Age-related Macular Degeneration

Breakup by Stage of Disease:

  • Early Stage
  • Intermediate Stage
  • Late Stage

Breakup by Route of Administration:

  • Intravenous Route
  • Intravitreal Route

Breakup by End User:

  • Hospitals
  • Ambulatory Surgical Center
  • Others

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

Who are the key players operating in the industry?

The report covers the major market players including:

Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Santen Pharmaceutical Co. Ltd.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: sales@imarcgroup.com

Follow us on Twitter: @imarcglobal

LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/